$45M Series B for QuantHealth to Scale AI-Driven Clinical Trial Simulations
Event summary
- $45M Series B led by Qumra Capital, with participation from nine other investors.
- Funds to scale AI-driven clinical trial simulations and expand therapeutic coverage.
- Simulated over 600 trials across 30 indications, achieving up to 90% predictive accuracy.
- Plans to expand to more than 40 indications in oncology, cardiometabolic, and inflammation.
The big picture
QuantHealth's funding round underscores the growing industry shift toward AI-driven decision-making in clinical trials, aiming to reduce costs and improve success rates. With over 90% of drugs failing in clinical development, predictive technologies are becoming essential for pharmaceutical companies seeking to optimize trial design and accelerate time-to-market.
What we're watching
- Adoption Pace
- Whether QuantHealth can sustain its growth trajectory as it expands into new therapeutic areas.
- Competitive Dynamics
- How the company will differentiate itself in an increasingly crowded AI-driven clinical trial space.
- Regulatory Impact
- The extent to which regulatory bodies may influence the adoption of simulation-first approaches in drug development.
Related topics